LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
23
Citations
NaN
KQI